Medigus Ltd. (NASDAQ:MDGS) Sees Significant Growth in Short Interest

Medigus Ltd. (NASDAQ:MDGS) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 126,200 shares, an increase of 123.8% from the September 15th total of 56,400 shares. Based on an average daily trading volume, of 2,950,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.6% of the company’s shares are sold short.

MDGS stock traded up $0.02 on Thursday, hitting $1.43. The company had a trading volume of 342 shares, compared to its average volume of 2,200,697. Medigus has a 12-month low of $1.35 and a 12-month high of $4.19. The stock’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.69.

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new stake in shares of Medigus in the 2nd quarter valued at about $52,000. Jane Street Group LLC purchased a new position in Medigus during the first quarter valued at $127,000. Citadel Advisors LLC acquired a new stake in shares of Medigus in the first quarter valued at about $216,000. Finally, Renaissance Technologies LLC acquired a new stake in Medigus during the second quarter worth about $452,000.

Medigus Company Profile

Medigus Ltd. engages in research and development of medical treatment for the gastrointestinal tract. Its product is the MUSE system, an endoscopic device to perform Transoral Fundoplication for the treatment of gastroesophageal reflux disease. The company was founded by Elazar Sonnenschein on December 9, 1999 and is headquartered in Omer, Israel.

Featured Article: Conference Calls

Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with MarketBeat.com's FREE daily email newsletter.